BiosanaPharma Sees Success In Omalizumab Trial

Phase I Study Shows Favorable Comparison To Novartis' Xolair Brand

 
• By Dave Wallace

BiosanaPharma has revealed success in a comparative Phase I trial for its BP001 omalizumab proposed biosimilar rival to Novartis’ Xolair.

84
The Omalizumab Trial Involved 84 Volunteers • Source: Shutterstock

More from Biosimilars

More from Products